mjl1717 Forum Hero

Topics: 960 Posts: 5,468
| | 01/09/04 - 03:12 PM  
 
|   #1 |
Cardiotoxicity of Adriamycin can be potentiated by which agent?
___________________ Smell the coffee! "Is That an Osler move??"
|
| meg Forum Guru
Topics: 62 Posts: 806
| | 01/09/04 - 03:41 PM  
 
|   #2 |
I think cyclophosphamide but I am not sure ! :roll:
|
| asmi Forum Hero
Topics: 1043 Posts: 4,609
| | 01/09/04 - 07:56 PM  
 
|   #3 |
Daunorubicin,methotrexate,cyclophosphamide,cytarabin.
|
| mjl1717 Forum Hero

Topics: 960 Posts: 5,468
| | 01/09/04 - 09:24 PM  
 
|   #4 |
answer -mitomycin
___________________ Smell the coffee! "Is That an Osler move??"
|
| asmi Forum Hero
Topics: 1043 Posts: 4,609
| | 01/09/04 - 11:55 PM  
 
|   #5 |
daunorubicin belongs to the same family of doxorubicin,right?
|
| meg Forum Guru
Topics: 62 Posts: 806
| | 01/10/04 - 05:53 AM  
 
|   #6 |
yes
|
| meg Forum Guru
Topics: 62 Posts: 806
| | 01/10/04 - 05:54 AM  
 
|   #7 |
mjl, how does mitomycin interact with adriamycin to enhance toxicity?
|
| asmi Forum Hero
Topics: 1043 Posts: 4,609
| | 01/10/04 - 12:42 PM  
 
|   #8 |
Then i think daunorubicin can also be one choice...to enhance doxorubicin(adriamycin) sideeffect.
|
| leftfoot Forum Elite
Topics: 29 Posts: 216
| | 01/25/04 - 07:59 PM  
 
|   #9 |
doxorubicin causes cardiotoxicity by forming free radicals. mitomycin does the same thing. when given together they both have synergistic effect and hence the toxicity of doxorubicin is enhanced. :wink:
|
| asmi Forum Hero
Topics: 1043 Posts: 4,609
| | 01/25/04 - 08:39 PM  
 
|   #10 |
thanks Dr patel 
|
| asmi Forum Hero
Topics: 1043 Posts: 4,609
| | 01/25/04 - 09:16 PM  
 
|   #11 |
http://www.drugs.com/xq/cfm/pageID_0/htm_d00218A1... to know which drugs should be avoided before taking adriamycin
|
| meg Forum Guru
Topics: 62 Posts: 806
| | 01/26/04 - 06:18 AM  
 
|   #12 |
thanks 
|
| usmleasr Forum Guru
Topics: 105 Posts: 970
| | 02/17/04 - 03:24 PM  
 
|   #13 |
thanks asmi... i learnt interesting things in this web page..FDA new areas
|
|
| |
| | | | | | | | | | | | | |